U.S. markets closed

VBI Vaccines Inc. (VBIV)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.5060+0.0443 (+9.59%)
At close: 04:00PM EST
0.5048 -0.00 (-0.24%)
After hours: 04:24PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close0.4617
Bid0.4927 x 800
Ask0.4900 x 800
Day's Range0.4500 - 0.5233
52 Week Range0.4500 - 2.7500
Avg. Volume859,790
Market Cap130.678M
Beta (5Y Monthly)1.67
PE Ratio (TTM)N/A
EPS (TTM)-0.2860
Earnings DateMar 06, 2023 - Mar 10, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for VBIV

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • VBI Vaccines, Inc.
    Analyst Report: Gilead Sciences, Inc.Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
    Fair Value
    Economic Moat
    6 days agoMorningstar
View more
  • Business Wire

    CEPI Boosts ‘Coronavirus X’ Vaccine Search With Expanded VBI Vaccines Deal

    OSLO, Norway & CAMBRIDGE, Mass., December 06, 2022--The Coalition for Epidemic Preparedness Innovations (CEPI) is expanding its world-leading portfolio of potential variant-proof coronavirus vaccines in a deal with VBI Vaccines Inc. (Nasdaq: VBIV) to advance the development of multivalent coronavirus shots that could be deployed against COVID-19 as well as a future ‘Coronavirus X’.

  • Business Wire

    VBI Vaccines Presents Additional Phase 1/2a Data from VBI-1901 in Recurrent GBM at the 2022 Society for Neuro-Oncology (SNO) Annual Meeting

    CAMBRIDGE, Mass., November 22, 2022--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that additional biomarker data from the Phase 1/2a study of VBI-1901, the Company’s cancer vaccine immunotherapeutic candidate in recurrent glioblastoma (GBM), were presented at the 27th Annual Meeting and Education Day of the Society for Neuro-Oncology (SNO), on Friday, November 18, 2022.

  • Business Wire

    VBI Vaccines to Participate in Upcoming Investor Conferences

    CAMBRIDGE, Mass., November 14, 2022--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that members of the management team will participate in analyst-led fireside chats at the following investor conferences: